Estradiol valerate

Bibliography

An asterisk (*) denotes an item that was particularly useful in the preparation of this issue of Population Reports. [1] ABDEL-SAYED, W.S., TOPPOZADA, H.K., SAID S.A., and EL-SAYED, O.K. Some metabolic and hormonal changes in women using long acting injectable contraceptives. Alexandria Journal of Pharmaceutical Sciences 3(1):29-32. Mar. 1989. [2] ABEYWICKREMA, D. (Family Planning Association of Sri Lanka) [Logistics and infection prevention] Personal communication, Dec. 29, 1993. [3] AD HOC CONSULTATIVE PANEL ON DEPOT MEDROXYPROGESTERONE ACETATE. Report to USAID of the Ad Hoc Consultative Panel on Depot Medroxyprogesterone Acetate, New York City, Dec. 7-8, 1978. Jul. 1980. 59 p. (Unpublished) [4] AHMAD, S., ISLAM, M.N., and RAHMAN, S. Determinants of acceptance of injectable contraception in Bangladesh. Dhaka, Bangladesh, Associates for Research Training and Computer Processing Ltd. and the National Institute of Population Research and Training, Nov. 1992. 156 p. [5] AKBAR, J., CHAKRABORTY, J., JAHAN, N., PHILLIPS, J.F., and SATTERWAITE, A.P., Dynamics of depot medroxyprogesterone acetate (DMPA) use effectiveness in the Matlab Family Planning Health Services Project. Presented at the 7th Annual Contributors Conference of Banngladesh Fertility Research Programme, Dhaka, Dec. 8-9, 1982. 12p. [6] AMATAYAKUL, K. The effects of Depo-Provera on carbohydrate, lipids and vitamin metabolism. Journal of Steroid Biochemistry 11(1B): 475-481. Jul. 1979. [7] AMATAYAKUL, K., SIVASSOMBOON, B., and SINGKAMANI, R. Effects of medroxyyprogessterone acetate on serum lipids, protein, glucose tolerance and liver function in Thai women. Contraception 21(3): 283-297. Mar. 1980. [8] AMATAYAKUL, K., SIVASOMBOON, B., and THANANGKUL, O. A study of the mechanism of weight gain in medroxyprogessterone acetate users Contraception 22(6): 605-622. Dec. 1980. [9] ANONYMOUS. Counseling about side effects improves contraceptive continuation. Network 12(2): 3. Sep. 1991. [10] ANONYMOUS UK: Beagle carcinogenicity studies no longer required for progestogens. Scrip World Pharmaceutical News, No. 430, Oct. 17, 1979. p. 3. [11] APELO, R.A., DE LA CRUZ, J.R., and CANCIO-LOPEZ, F. Acceptability of injectable contraception in the Philippines. IPPF Medical Bulletin 8(2): 1-2. Apr. 1974. [12] ARIWONGSE, B.C. An overview of the FPNP injectable programme. In: Palan, V.T. and Nawi, M., eds. Recent advances in contraceptive technology: Proceedings of the seminar held 14-20 Oct. 1987 in Chiang Mai, Thailand, International Planned Parenthood Federation, East & Southeast Asia and Ocenia Region. 1987. p. 94-96. [13] ASHMAN, J.A.M. Monthly injectable contraceptives and breast cancer. Thesis for Master of Science degree, University of Washington, [Seattle, Washington], 1990. 77 p. [14] ASSOCIATION OF REPRODUCTIVE HEALTH PROFESSIONALS (ARHP). and UNIVERSITY OF FLORIDA (UF). Family planning update: Injectable Contraceptive. [Video] Washington, D.C. and Jacksonville, Florida, ARHP, and UF, Sep. 3, 1992. [15] AYDINLIK, S. (Schering) [Teratogenic effects of NET-EN] Personal communication to H.L. Ellis, Ellis Pharmaceutical Consulting, May 31, 1994. [16] AYLWARD, B., KANE, M., MCNAIR-SCOTT, R., and HU, D.J. Risk of human immunodeficiency virus and Hepatitis-B virus transmission through unsafe injections: Model-based estimates. [Draft] 1994. 22 p. [17] BABCOCK, J.C., GUTSELL, E.S., HERR, M.E., HOGG, J.A. STUCKI, J.C., BARNES, L.E., AND DOULIN, W.E. 6-Methyl-17-Hydroxyprogesterone 17-acylates: A new class of potent progestins. Journal of the American Chemical Society 80(pt. 2): 2904-2905. Apr.-Jun. 1958. [18] BACHMAN, G. (SOMRC) [Injectables in social marketing programs] Personal communication, Apr. 28, 1995. [19] BAKOUAN, D., SEBGO, P., ASKEW, I., OUEDRAOGO, Y., TAPSOBA, P., VIADRO, C., and KANON, S. Analyse situationnelle du programme de planification familiale au Burkina Faso. [Situation analysis of the family planning program in Burkina Faso.] [FRE] [Ougadougou]. Burkina Faso, Burkina Faso. Department of Health, Feb. 1992. 69 p. [20] BALDWIN, G.B. The McCormick Family Planning Program in Chiang Mai, Thailand. Studies in Family Planning 9(12): 300-312. Dec. 1978. [21] BANERJEE, S.K., BAVEJA, R., BHATT, R.V., et al. Return of fertility following discontinuation of an injectable contraceptie-Norethisterone oenanthate (NET EN) 200mg dose. Contraception 34(6): 573-582. Dec. 1986. [22] BANGLADESH. MINISTRY OF HEALTH. NATIONAL INSTITUTE FOR POPULATION RESEARCH AND TRAINING (NIPORT). and MITRA AND ASSOCIATES (MA). and DEMOGRAPHIC AND HEALTH SURVEYS (DHS). MACRO INTERNATIONAL. Bangladesh Demographic and Health Survey 1993-94: Preliminary report. Dhaka, Bangladesh, and Calverton, Maryland, NIPORT, and MA. and DHS, Jul. 1994. 37 p. [23] BASNAYAKE, S. (Family Planning Association of Sri Lanka) [Injectables in Sri Lanka] Personal communication, Apr. 19, 1995. [24] BASNAYAKE, S. A study of 157 women who conceived after discontinuation of Depo Provera. [Colombo, Sri Lanka, Family Planning Association of Sri Lanka], Oct. 1981. 9 p. [25] BASNAYAKE, S. A study of Depo-Provera users in a family planning clinic in Sri Lanka. Presented at the Family Planning Association of Sri Lanka 25th Anniversary Scientific Congress, [Colombo, Sri Lanka], Mar. 26-28 13 p. [26] BASSOL, S. and GARZA-FLORES, J. Review of ovulation return upon discontinuation of once-a-month injectable contraceptives. Contraception 49(5): 441-453. May 1994. [27] BASSOL, S., HERNANDEZ, C., NAVA, M.P., TRUJILLO, A.M., AND LUZ DE LACRUZ, D. A comparative study on the return to ovulation following chronic use of once-a-month injectable contraceptives. Contraception 51(5): 307-311. May 1995. [28] BECTON DICKINSON AND COMPANY (B-D). SoloShot syringe. [Foldout brochurel Franklin Lakes, New Jersey, B-D, 1991. 6 p. [29] BELSEY, E.M., D'ARCANGUES, C., CARLSON, N., AND WORLD HEALTH ORGANIZATION. TASK FORCE ON LONG-ACTING SYSTEMIC AGENTS FOR FERTILITY REGULATION. Determinants of menstrual bleeding patterns among women using natural and hormonal methods of contraception: 2. The influence of individual characteristics. Contraception 38(2): 243-257. Aug. 1988. [30] BELSEY, E.M. AND FARLEY, T.M.M. The analysis of menstrual bleeding patterns: A review. Contraception 38(2): 129-156. Aug. 1988. [31] BELSEY, E.M., MACHIN, D., AND D'ARCANGUES, C. The analysis of vaginal bleeding patterns by fertility regulating methods. Contraception 34(3): 253-260. Sep. 1986. [32] BELSEY, E.M., PEREGOUDOV, S., AND TASK FORCE ON LONG-ACTING SYSTEMIC AGENTS FOR FERTILITY REGULATION, SPECIAL PROGRAMME OF RESEARCH, DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION. Determinants of menstrual bleeding patterns among women using natural and hormonal methods of contraception: 1. Regional variations. Contraception 38:227-242. 1988. [33] BELSEY, E.M. and WORLD HEALTH ORGANIZATION. TASK FORCE ON LONG-ACTING SYSTEMIC AGENTS FOR FERTILITY REGULATION. The association between vaginal bleeding patterns and reasons for discontinuation of contraceptive use. Contraception 38(2): 207-225. Aug. 1988. [34] BENNETT, K. (Upjohn) [Side effects and registration of DMPA] Personal communication, Dec. 19, 1994 and Feb. 21, 1995. [35] BENNETT, R.C. Depo medroxyprogesterone acetate (Depo Provera) for contraception. Jun. 19, 1992. 15 p. (Unpublished) [36] BENSON, R.C. and PERNOLL, M.L. Benson and Pernolls handbook of obstetrics and gynecology. 9th ed. New York, McGraw-Hill, 1994. 817 p. [37] BINZEN, S. Improving contraceptive supply management. Family Planning Manager 1(4): 1-20, Sep.-Oct. 1992. [38] BISGROVE, E. (Family Health International) [DMPA and bone density] Personal communication, Jun. 28, 1995. [39] BLOCH, B. Depot medroxyprogesterone acetate (Depo-Provera) as a contraceptive preparation. South African Medical Journal 45(28): 777-780. Jul. 17, 1971. [40] BRACKEN, M.B. Oral contraception and congenital malformations in offspring: a review and meta-analysis of the prospective studies. Obstetrics and Gynecology 76(3,Pt.2): 552-557. Sep. 1990. [41] BRAT, T.M. Acceptability of Depo-Provera as a reliable contraceptive method. [Abstract] In: Kleinman, R. and Pickles, V.R. eds. In: Kleinman, R. and Pickles, V.R., eds. 7th World Congress, Fertility and Sterility, Oct. 1971. Amsterdam, Excerpta Medical Foundation, 1971. (International Congress Series No. 243a)p. 85. [42] BRIEND, A., FAUVEAU, V., and CHAKRABORTY, J. Contraceptive use and breast-feeding duration in rural Bangladesh. European Journal of Clinical Nutrition 45(7): 341-346. Jul. 1991. [43] BROOKS, G.G. Anaphylactoid shock with medroxyprogesterone acetate: A case report. Journal of the Louisiana State Medical Society 126(11): 397-399. Nov. 1974. [44] BRUZZI, P., NEGRI, E., LA VECCHIA, C., DECARLI, A., PALLI, D., PARAZZINI, F., and ROSSELLI DEL TURCO, M. Short term increase in risk of breast cancer after full term pregnancy. British Medical Journal 297(6656):1096-1098. Oct. 29, 1988. [45] CAILLOUX, L. (John Snow) [DMPA shipments by USAID] Personal communication, Feb. 28, 1995. [46] CALDWELL, J.C. and CALDWELL, P. What does the Metlab fertility experience and really show? [Canberra, Australia], Australian National University. National Centre for Epidemiology and Population Health, 1992. (Health Transition Working Paper No. 14) 27 p. [47] CHAUDHURI, C., BHOWMIK, T., and MUKHERJEA, M. Alterations in blood sugar, protein, and lipid levels in Indian women by norethisterone enanthate. International Journal of Fertility 32(3):240-244. May-Jun. 1987. [48] CHEVANNES, B. and MCDONALD, O. (Jamaican National Family Planning Board) [Injectables in Jamaica] Personal Communication, Dec. 22, 1993. [49] CHEZ, R.A. Proceedings of the symposium Progesterone, progestins, and fetal development. Fertility and Sterility 30(1): 16-26. Jul. 1978. [50] CHINVANTHANANOND, P. and SAMRANSAMRUAJKIT, S. New regimen of injectable contraceptives. Journal of the Medical Association of Thailand 70(4): 198-203. Apr. 1987. [51] COLEMAN, P. (Population Communication Services) [DMPA in the Philippines] Personal communication, Mar. 14, 1994. [52] COSTA, T.H.M. and DOREA, J.G. Concentration of fat, protein, lactose and enery in milk of mothers using hormonal contraceptives. Annals of Tropical Paediatrics 12(2): 203-209. 1992. [53] COUPLES CHOICE. Facts about Depo-Provera. Manila Bulletin, May 1, 1994. [54] CROMER, B.A., SMITH, R.D., BLAIR, J.M., DWYER, J., and BROWN, R.T. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception. Pediatrics 94(5): 687-694. Nov. 1994. [55] CROWLEY, J. (USAID) [Shelf life of DMPA] Personal communication, Dec. 22, 1994. [56] CROXATTO, H.B. and DIAZ, S. Post-partum contraception. In: Diczfalusy, E. and Bygdeman, M., eds. Fertility regulation today and tomorrow. New York, Raven, 1987. (Serono Symposia Publications Vol. 36) p. 181-195. [57] CUNDY, T., CORNISH, J., EVANS, M.C., ROBERTS, H., and REID, I.R. Recovery of bone density in women who stop using medroxyprogesterone acetate. British Medical Journal 308(6923): 247-248. Jan. 22, 1994. [58] CUNDY, T., EVANS, M., ROBERTS, H., WATTIE, D., AMES, R., and REID, I.R. Bone density in women receiving depot medroxyprogesterone acetate for contraception. British Medical Journal 303(6793): 13-16. Jul. 6, 1991. [59] CZEIZEL, A.E. and KODAJ, I. A changing pattern in the association of oral contraceptive and the different groups of congenital limb deficiencies. Contraception 51(1): 19-24. Jan. 1995. [60] D'ARCANGUES, C. (WHO) [Injectable research] Personal communication, Mar. 31, 1994. [61] DAHLBERG, K. Some effects of depo-medroxyprogesterone acetate (DMPA): Observations in the nursing infant and in the long-term user. International Journal of Gynaecology and Obstetrics 20(1): 43-48. Feb. 1982. [62] DAS GUPTA, A. (JHSPH/PCS/Bangladesh) [Injectable contraception interviews] Personal communication, [1994]. [63] DATEY, S., GAUR, L.N., and SAXENA, B.N. Vaginal bleeding patterns of women using different contraceptive methods (Implants, injectables, IUDs, oral pills)An Indian experience. Contraception 51(3): 155-165. Mar. 1995. [64] DAVIS, M.E. and WIED, G.L. Long-acting progestational agents. Geburtshilfe und frauenheilkunde 17(10): 916-928. 1957. [65] DE CEULAER, K., GRUBER, C., HAYES, R., and SERJEANT, G.R. Medroxyprogesterone acetate and homozygous sickle-cell disease. Lancet 2(8292): 229-231. Jul. 31, 1982. [66] DIAS, J. and DIAZ, M. Quality of care in family planning in Latin America. Advances in Contraception 9(2): 117-128. 1993. [67] DISAIA, P.J. Ovarian neoplasms. In: Scott, J.R., Disaia, P.J., Hammond, C.B., and Spellacy, W.N. eds. Danforth's Obstetrics and gynecology. 7th ed. Philadelphia, J.B. Lippincott, 1994. p. 969-1018. [68] DKT INTERNATIONAL (DKT). 1993 contraceptive social marketing statistics. Washington, D.C., DKT, Jul. 1994. 6 p. [69] DONEGA, W.L. Diseases of the breast. In: Danforth, D.N. and Scott, J.R., eds. Obstetrics and gynecology. 5th ed. Philadelpia, J.B. Lippincott, 1986. p. 1156-1175. [70] DUNCAN, G.W. and KIRTON, K.T. Depo-Provera: Pharmacology and toxicology: In: Zambrano, D., ed. Depo-provera (medroxyprogesterone acetate) for contraception: A current perspective of scientific, clinical and social issues. Proceedings of an international symposium held on 19-20 Nov. 1992. Oxford, England, Oxford Clinical Communications, 1992. p. 7-25. [71] EL ARIFEEN, S. and MOOKHERJI, S. The urban MCH-FP initiative: A partnership for urban health and family planning in Bangladesh. An assessment of programme needs in zone 3 of Dhaka City. [Dhaka], Concerned Women for Family Planning. and Bangladesh. Ministry of Health and Family Welfare. and Centre for Health and Population Research, 1995. 59 p. [72] EL-MAHGOUB, S., KARIM, M., and AMMAR, R. Long-term use of depot medroxy progesterone acetate as a contraceptive. Acta Obstetricia et Gynecologica Scandinavica 51: 251-255. 1972. [73] EL-ZANATY, F.H., SAYES, H.A.A., ZAKY, H.H.M., and WAY, A.A. Egypt Demographic and Health Survey 1992. Cairo. and Calverton, Maryland, National Population Council. and Macro International, Nov. 1993. 317 p. [74] ELLIS, H. (ELLIS Consulting) [Norethisterone-Enanthate and Mesigyna] Personal communication, Nov. 3, 1993. [75] ENK, L., LANDGREN, B.-M., LINDBERG, U.-B., SILFVERSTOLPE, G., and CRONA, N. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. Hormone and Metabolic Research 24(2): 85-89. Feb. 1992. [76] FAHMY, K., ABDEL-RAZIK, M., SHAARAWAY, M., AL-KHOLY, G., SAAD, S., WAGDI, A., and AL-AZZONY, M. Effect of long-acting progestagen-only injectable contraceptives on carbohydrate metabolism and its hormonal profile. Contraception 44(4): 419-430. Oct. 1991. [77] FAHMY, K., KHAIRY, M., ALLAM, G., GOBRAN, F., and ALLOUSH, M. Effect of depo-medroxyprogesterone acetate on coagulation factors and serum lipids in Egyptian women. Contraception 44(4): 431-444. Oct. 1991. [78] FAJUMI, J.O. Alterations in blood lipids and side effects induced by Depo-Provera in Nigerian women. Contraception 27(2): 161-175. Feb. 1983. [79] FAJUMI, J.O. The effects of depo-provera on serum protein levels in Nigerian women. Journal of Steroid Biochemistry 20(2): 581-583. Feb. 1984. [80] FALASE, E.A.O., OTOLORIN, E.O., and LADIPO, O.A. Experience with the use of depo-medroxyprogesterone acetate in a Nigerian population. African Journal of Medicine and Medical Sciences 17(4): 209-213. Dec. 1988. [81] FAMILY HEALTH INTERNATIONAL (FHI). Injectables. [Loose leaf binder] Research Triangle Park, North Carolina, FHI, 1993. (Contraceptive Technology Update Series) [82] FERRAZ, E.H., FERREIRA, J.Q., and RUTENBERG, N. Pesquisa sobre sade familiar no Nordeste Brasil 1991. [Survey of family health in northeast Brazil.] [POR] Rio de Janeiro. and Columbia, Maryland, Sociedade Civil Bem-Estar Familiar no Brasil. and Macro International, Oct. 1992. 247 p. [83] FINGER, W.R. Injectables use increasing rapidly. Network 15(4): 20. Jun. 1995. [84] FOREIT, J. (Population Council) [Introducing DMPA in Latin America] Personal communication, Mar. 7, 1994. [85] FOTHERBY, K. Factors affecting the duration of action of the injectable contraceptive norethisterone enanthate. Contraceptive Delivery Systems 2(3): 249-257. Jul. 1981. [86] FOTHERBY, K., BENAGIANO, G., TOPPOZADA, H.K., ABDEL-RAHMAN, A., NAVAROLI, F., ARCE, B., RAMOS-CORDERO, R., GUAL, C., LANDGREN, B.-M., and JOHANNISSON, E. A preliminary pharmacological trial of the monthly injectable contraceptive Cycloprovera. Contraception 25(3): 261-272. Mar. 1982. [87] FOTHERBY, K., SHI, Y.-E., HOWARD, G., EDLER, M.G., and MUGGERIDGE, J. Return of ovulation and fertility in women using norethisterone oenanthate. Contraception 29(5): 447-455. May 1984. [88] FRASER, I.S. A survey of different approaches to management of menstrual disturbances in women using injectable contraceptives. Contraception 28(4): 385-397. Oct. 1983. [89] FRASER, I.S. Vaginal bleeding patterns in women using once-a-month injectable contraceptives. Contraception 49(4): 399-420. Apr. 1994. [90] FUTURES GROUP. Integrating Depo-Provera in Nepal's social marketing initiative: What mechanisms are being developed to ensure high quality services? SOMARC III Highlights, No. 8. Dec. 1993. 2 p. [91] GARCEAU, R. (Upjohn) [Depo in India] Personal communication, Feb. 3, 1994. [92] GARDNER, J.M. and MISHELL, D.R., Jr. Analysis of bleeding patterns and resumption of fertility following discontinuation of a long acting injectable contraceptive. Fertility and Sterility 21(4): 286-291. Apr. 1970. [93] GARZA-FLORES, J., DE LA CRUZ, D.L., VALLES DE BOURGES, V., SANCHEZ- NUNCIO, R., MARTINEZ, M., FUZIWARA, J.L., and PEREZ-PALACIOS, G. Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism. Contraception 44(1): 61-71. Jul. 1991. [94] GIWA-OSAGIE, O.F. and WORLD HEALTH ORGANIZATION. Metabolic effects of once-a-month combined injectable contraceptives. Contraception 49(5): 421-433. May 1994. [95] GOODSMITH, L. (Population Communication Services) [DMPA in Guinea] Personal communication, Jun. 13, 1995. [96] GRABOWSKY, M., HADLER, S., CHEN, B., and BOND, W. Risk of human immunodeficiency virus or Hepatitis-B virus transmission through jet injectors or needles and syringes. [Draft] Aug. 1994. 22 p. [97] GRAY, R. (Johns Hopkins School of Public Health) [Injectable services] Personal communication, Dec. 2, 1993. [98] GRAY, R.H. Depot medroxyprogesterone and risk of breast cancer. [Letter] British Medical Journal 299(6707): 1099. Oct. 28, 1989. [99] GRAY, R.H. Reduced risk of pelvic inflammatory disease with injectable contraceptives. Lancet 1(8436): 1046. May 4, 1985. [100] GRAY, R.H. and PARDTHAISONG, T. The authors' response to Hogue. American Journal of Epidemiology 134(8): 816-817. 1991. [101] GRAY, R. and PARDTHAISONG, T. In utero exposure to steroid contraceptives and survival during infancy. American Journal of Epidemiology 134(8): 804-811. Oct. 15, 1991. [102] GRAY, R.H., PARDTHAISONG, T., MCDANIEL, E.B., and DOYLE, P. The timing of the first injection of Depo Provera. [Letter to the editor] IPPF Medical Bulletin 9(5): 3-4. Oct. 1975. [103] GRAY, R.H., PARKER, R.A., and DIETHELM, P. Vaginal bleeding disturbances associated with the discontinuation of long-acting injectable contraceptives. British of Obstetrics and Gynaecology 88(3): 317-321. Mar. 1981. [104] GREENSPAN, A.R., HATCHER, R.A., MOORE, M. ROSENBERG, M.J., and ORY, H.W. The association of depo-medroxyprogesterone acetate and breast cancer. Contraception 21(6): 563-569. Jun. 1980. [105] GRIFFIN, M., HEATON, D.A., and MCEWAN, J.A. Long-term use of an injectable contraceptive: Effect of depot-norethisterone oenanthate on carbohydrate metabolism. Contraception 37(1): 53-60. Jan. 1988. [106] GRUBB, G. Critique of Pardthaisong and Gray in utero exposure to steroid contraceptives and outcome of pregnancy. May 29, 1992. 4 p. (Unpublished) [107] GULATI, K., MAPA, M.K., GUPTA, A.N., SINGH, P.M., and DEVI, P.K. Norethisterone oenanthate as an injectable contraceptive in two treatment schedules in interval subjects. Asia-Oceania Journal of Obstetrics and Gynaecology 10(3): 281-286. Sep. 1984. [108] HAIBA, N.A., EL-HABASHY, M.A., SAID, S.A. DARWISH, E.A., ABDEL-SAYED, W.S., and NAYEL, S.E. Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters. Contraception 39(6): 619-632. Jun. 1989. [109] HALL, P.E. (World Health Organization) [Injectable contraceptives] Personal communication, Jun. 1, 1993 and Apr. 24, 1995. *[110] HALL, P.E. and WORLD HEALTH ORGANIZATION. TASK FORCE ON RESEARCH ON INTRODUCTION AND TRANSFER TECHNOLOGIES FOR FERTILITY REGULATION. The introduction of Cyclofem into national family planning programmes: Experience from studies in Indonesia, Jamaica, Mexico, Thailand and Tunisia. Contraception 49(5): 489-507. May 1994. [111] HARDON, A.P. The needs of women versus the interests of family planning personnel, policy-makers and researchers: Conflicting views on safety and acceptability of contraceptives. Social Science and Medicine 35(6): 753-766. 1992. [112] HAREL, S., BIRO, F.M., and KOLLAR, L.M. Depo-Provera in adolescents: Effects of early second injection or prior oral contraception. Journal of Adolescent Health 16(5): 379-384. May 1995. [113] HART, C., LAMA, U.C. SHYAM, and PROPER, W. (John Snow) [Injectables] Personal communication, Apr. 28, 1995. [114] HART, C. (John Snow) [Shortening the pipeline for injectables] Personal communication, Jan. 20, 1995. [115] HANSEN, E. O., EL-NAHAL, N. and EL-HUSSEIN, M. Acceptability of the once-a-month injectable contraceptives Clyclofem and Mesigyna in Egypt. Contraception 49(5): 469-488. May 1994. [116] HATCHER, R.A., TRUSSELL, J., STEWART, F., STEWART, G.K., KOWAL, D., GUEST, F., CATES, W., Jr., and POLICAR, M.S. Contraceptive technology. 16th rev. ed. New York, Irvington Publishers, 1994. 747 p. [117] HEATON, L. Background briefing book for CRS social marketing project in Nepal: Based on a review of secondary research. Glastonbury, Connecticut, Futures Group, International, Aug. 1993. 127 p. [118] HESLING, C. (UNFPA) [Procurement and logistics of injectables] Personal communication, Dec. 29, 1993 and Mar. 9, 1995. [119] HESS, R. (PCS) [Social drama in Pakistan] Personal communication, Oct. 5, 1993. [120] HOGUE, C.J.R. Invited commentary: The contraceptive technology tigh-rope. American Journal of Epidemiology 134(8): 812-815. 1991. [121] HOWARD, G., BLAIR, M., DAVIS, H., and TREACY, M. The effect of norethisterone oenanthate on the full blood count. British Journal of Family Planning 8(4): 125-129. Jan. 1983. [122] HOWARD, G., BLAIR, M., FOTHERBY, K., ELDER, M.G., and BYE, P. Seven years clinical experience of the injectable contraceptive, norethisterone oenanthate. British Journal of Family Planning 11(1): 9-16. Apr. 1985. [123] HOWARD, G., BLAIR, M., FOTHERBY, K., TRAYNER, I., HAMAWI, A., and ELDER, M.G. Some metabolic effects of lon-term use of the injectable contraceptive norethisterone oenanthalate. Lancet (8269): 423-425. Feb. 20, 1982. [124] HOWARD, G., MYATT, L., and ELDER, M.G. The effects of intramuscular norethisterone oenanthate used as a contraceptive on intravenous glucose tolerance and on blood coagulation factors VII and X. British Journal of Obstetrics and Gynaecology 84(8): 618-621. Aug. 1977. [125] HUBER, D. A case study: DMPA reintroduced in the Philippines. Presented at the Cooperating Agencies Meeting of the US Agency for International Development, Washington, D.C., Feb. 23, 1994. 4 p. [126] HUBER, D.G., KHAN, A.R., BROWN, K., MALAKAR, M., and WAIT, G. Oral and injectable contraceptives: Effects on breast milk and child growth in Bangladesh. In: Zatuchni, G.I., Labbok, M.H., and Sciarra, J.J., eds. Research frontiers in fertility regulation. Hagerstown, Maryland, Harper & Row, 1980. (PARFR Series on Fertility Regulation) p. 127-135. [127] HUEZO, C. and MALHOTRA, U. Choice and use-continuation of methods of contraception: A multicentre study. London, International Planned Parenthood Federation, 1993. p. 97, 108. [128] HUQUE, A.A.Z, KOBLINSKY, M.A., and PHILLIPS, J.F. Operational barriers to implementing a domiciliary injectable contraceptive programme in rural Bangladesh. Presented at the Bangladesh Population Association Conference, Dhaka, Aug. 1984. 16 p. [129] INDIAN COUNCIL OF MEDICAL RESEARCH. NATIONAL PROGRAMME OF RESEARCH IN HUMAN REPRODUCTION. TASK FORCE ON HORMONAL CONTRACEPTION. Comparative evaluation of contraceptive efficacy of norethisterone oenanthate (200mg) injectable contraceptive given every two or three months. Contraception 30(6): 561-574. Dec. 1984. [130] INDIAN COUNCIL OF MEDICAL RESEARCH. TASK FORCE ON HORMONAL CONTRACEPTION. A multicentre Phase III comparative study of two hormonal contraceptive preparations NET-OEN (50 mg) plus E2 valerate (5 mg) given every month and NET-OEN (200 mg) given every 2 months as intramuscular injection. A report of a 12-month study. Contraception 42(2): 179-190. Aug. 1990. [131] INDONESIA CENTRAL BUREAU OF STATISTICS (CBS). and NATIONAL FAMILY PLANNING COORDINATING BOARD (NFPCB). and MINISTRY OF HEALTH (MOH). and DEMOGRAPHIC HEALTH SURVEYS (DHS). MACRO INTERNATIONAL. Indonesia Demographic and Health Survey 1994: Preliminary report. [Jakarta, Indonesia]. and Calverton, Maryland, CBS. and MOH. nd NFPCB., and DHS, Jan. 1995. 67 p. [132] INDONESIAN SOCIETY OF OBSTETRICS AND GYNECOLOGY (POGI). and JHPIEGO Corporation. and NATIONAL FAMILY PLANNING COORDINATING BOARD (BKKBN). Refresher course handout: DMPA. [Jakarta]. and Baltimore, Apr. 1995. 33 p. (Mimeo) [133] INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH, BANGLADESH (ICDDR,B). Injectable contraceptives: The use of reusable versus disposable needles and syringes. [Dhaka], Bangladesh, ICDDR,B, Dec. 1987. (MCH-FP Extension Projet Briefing Paper No. 3) 3 p. [134] INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH, BANGLADESH (ICDDR,B). The case for one brand of injectables within the Bangladesh family planning program. [Dhaka], Bangladesh, ICDDR,B, Mar. 1991. (MCH-FP Extension Project Briefing Paper No. 16) 3 p. [135] INTERNATIONAL INSTITUTE FOR POPULATION SCIENCES (IIPS). National family health survey (MCH and family planning): India 1992-93. Introductory report. Bombay, IIPS, Oct. 1994. 91 p. [136] INTERNATIONAL PLANNED PARENTHOOD FEDERATION (IPPF), INTERNATIONAL MEDICAL ADVISORY PANEL. Statement on injectable contaception. IPPF Medical Bulletin 16(6): 3-4 Dec. 1982. *[137] INTERNATIONAL PLANNED PARENTHOOD FEDERATION (IPPF). Medical and service delivery guidelines for family planning. London, IPPF, 1992. 169 p. [138] INTERNATIONAL PLANNED PARENTHOOD FEDERATION (IPPF). Statement on injectable contraception. London, IPPF, 1992. 6 p. (Mimeo) *[139] ISAACS, W.A. and HAYHOE, F.G.J. Steroid hormones in sickle-cell disease. Nature 215(5106): 1139-1142. Sept. 9, 1967. [140] JABRE, B., KAIDBEY, M., STOREY, D., JAROUDI, L., MORGAN, W., and WAFAI, M. Madmiuun and Murah: A summary of findings from family planning research in Egypt, 1988-1993. [ENG, ARA] Baltimore, Johns Hopkins School of Public Health, Center for Communication Programs, 1994. 32 p. [141] JANERICH, D.T. and HOFF, M.B. Evidence for a crossover in breast cancer risk factors. American Journal of Epidemiology 116(5): 737-742. Nov. 1982. [142] JATO, M. Tanzania: Communication campaign sparks a growing awareness of family planning needs, methods and practice in Dar-es-Salaam, Kisarawe and Mwanga 1994. [Draft] Sep. 1994. 47 p. [143] JIMENEZ, J., OCHOA, M., SOLER, M.P., and PORTALES, P. long-term follow-up of children breastfed by mothers receiving depo-medroxyprogesterone acetate. Contraception 30(6): 523-533. Dec. 1984. [144] JOHAL, K. (JSI, JHPIEGO) [Injectable training] Personal communication, Dec. 27, 1994. [145] JOHAL, S. (IPPF) [Procurement of injectbales] Personal communication, Feb. 10, 1995. [146] JOHN, H.M. Use of Depo in a community health program in southern India. In: World Neighbors: Second Asian Regional Workshop on Injectable Contraceptives. Oklahoma City, Oklahoma, World Neighbors, 1982. p. 18-21. [147] JOHNS HOPKINS UNIVERSITY. POPULATION COMMUNICATION PROGRAMS (PCS). Pakistan: Report on technical assistance to the Ministry of Population Welfare, Government of Pakistan. Aug. 1990-Jun. 30, 1993. Baltimore, PCS, 1993. (Mimeo) [148] JORDAN, A. FDA requirements for nonclinical testing of contraceptive steroids. Contraception 46(6): 499-509. Dec. 1992. [149] JUNKMANN, K. Uber protrahiert wirksame Gestagene. [On the prolonged action of gestagens.][GER] Nuny-Schmeidebergs Archiv fr Experimentelle Pathologie und Pharmakologie 223: 244-253. 1954. [150] JUNKMANN, K. and WITZEL, H. Chemie and pharmakologie von Steroid-homon-Estern. [Chemistry and pharmacology of steroidal hormone esters.] [GER] Zeitschrift fr Vitamin Hormon, und Fermentforschung 9:97-143. 1958. [151] KALTER, H. and WARKANY, J. Congenital malformations: 1. Etiologic factors and their role in prevention. New England Journal of Medicine 308(8): 424-431. Feb. 24, 1983. [152] KARIM, M., AMMAR, R., ELMAHGOUB, S., EL GANZOURY, B., FIKRI, F., and ABDOU, I. Injected progestogen and lactation. British Medical Journal 1(5742): 200-203. Jan. 23, 1971. [153] KATIUANJO, P., TITUS, S., ZAUANA, M., and BOERMA, J.T. Namibia Demograhic and Health Survey 1992. Windhoek, Namibia. and Columbia, Maryland, Namibia Ministry of Health and Social Services. and Macro International. Demographic and Health Surveys, May 1993. 221 p. [154] KAUNTIZ, A. (University of Florida)_ [Depo-Provera] Personal communication, Jan. 28, 1994 and Jul. 7, 1995. [155] KEITH, L. and BERGER, G.S. The relationship between congenital defects and the use of exogenous progestational contraceptive hormones during pregnancy: A 20-year review. International Journal of Gynaecology and Obstetrics 15(2): 115-124. Sept.-Oct. 1977. [156] KENYA. NATIONAL COUNCIL FOR POPULATION AND DEVELOPMENT. CENTRAL BUREAU OF STATISTICS (CBS). and MACRO INTERNATIONAL (MI). DEMOGRAPHIC AND HEALTH SURVEYS. Kenya Demographic and Health Survey 1993. Nairobi. and Calverton, Maryland, CBS. and MI, May 1994. 278 p. [157] KESSERU, E.V., AYDINLIK, S., and ETCHEPAREBORDA, J.J. Multicentred, Phase III clinical trial of norethisterone enanthate 50 mg plus estradiol valerate 5 mg as a monthly injectable contraceptive; final three-year report. Contraception 50: 329-337. Oct. 1994. [158] KESSERU, E.V. and TOZZINI, R. Monthly injectable contraception with norethisterone enanthate plus estradiol valerate. In: Female contraception. Berlin, Springer-Verlag, 1988. p. 221-226. [159] KEW, M.C., SONG, E., MOHAMMED, A, and HODKINSON, J. Contraceptive steroids as a risk factor hepatocellular carcinoma: A case/control study in South African black women. Hepatology 11(2): 298-302. Feb. 1990. [160] KIM, Y.-M., MARANGWANDA, C., DLODLO, B., and KOLS, A. Involving men in family planning: The male motivation and family planning method expansion project, 1993-1994. Baltimore, Johns Hopkins School of Public Health, Center for Communication Program, Jun. 1995. (Forthcoming CCP Working Paper) [161] KINCAID, D.L., COLEMAN, P.L., and RIMON, J.G. 2nd. The national communication campaign of the Philippines 1993-1994: Key research findings. Baltimore, Johns Hopkins Center for Communication Programs, 1994. 25 p. (Mimeo) [162] KLUGMAN, B. The politics of contraception in South Africa. Womens Studues International Forum 13(3): 261-271. 1990. [163] KNODEL, J. (Institute of Population Studies, Chulalongkorn University) [Vietnam survey findings] Personal communication, May 29, 1995. [164] KOENIG, M.A., ROB, U., KHAN, M.A, CHAKRABORTY, J., and FAUVEAU, V. Contraceptive use in Matlab, Bangladesh in 1990: Levels, trends, and explanations. Studies in Family Planning 23(6): 352-364. [165] KOETSAWANG, S. Experience with injectable cotnraceptives in Thailand, British Journal of Family Planning 12(4, Suppl.):6-14, Jan. 1987. [166] KOETSAWANG, S. Once-a-month injectable contraceptives: Efficacy and reasons for discontinuation. Contraception 49(4): 387-397. Apr. 1994. [167] KOETSAWANG, S. (Siriraj Family Planning Research Centre) [Thai experience with NET EN and DMPA] Personal communication, Jun. 3, 1993 and Apr. 19, 1995. [168] KOETSAWANG, S., BOONYAPRAKOB, V., SUVANICHATI, S., and PAIPEEKUL, S. Long-term study of growth and development of children breastfeed by mothers receiving Depo-Provera (medroxyprogesterone acetate) during lactation. In: Zatuchni, G.L., Goldsmith, A., Shelton, J.D., and Sciarra, J.J., eds. Long-acting contraceptive delivery systems. Philadelphia, Harper & Row, 1984. p. 378-387. [169] KOETSAWANG, S., SRISUPHANDIT, S., SRIVANABOON, S., BHIRALEUS, P., RACHAWAT, D., KIRIWAT, O., and KOETSAWANG, A. Intramuscular depomedroxyprogesterone acetate for contraception. Journal of the Medical Association of Thailand 57(8): 396-406. Aug. 1974. [170] KONATE, D.L., SINARE, T., and SEROUSSI, M. Enquete Demographique et de Sante Burkina Faso 1993. [Demographic and Health Survey Burkina Faso 1993.][FRE] Quagadougou, Burkina Faso, Burkina Faso National Institute of Statistics and Demography. and Macro International, Jun. 1994. 296 p. [171] KOUAKOU KOUASSI, L., KOUAME, K., and HUNTINGTON, D. Analyse situationnelle du programme d'extension des services de planification familiale en Cote d'lvoire. [Situation analysis of the program to extend family planning services in Cote d'lvoire.][FRE] [Abidjan], Cote d'lvoire, Association lvoriene Pour Le Bien-etre Familial. and Population Council, Sep. 1992. 62 p. [172] KRAYACICH DE ODDONE, N., SHEDLIN, M.G., WELSH, M., POTTS, M., and FELDBLUM, P. Paraguayan pharmacies and the sale of pseudo-abortifacients. Journal of Biosocial Science 23(2): 201-209. Apr. 1991. [173] KRISTENSEN, D.D. (Program for Appropriate Technology in Health) [Delivery systems and shelf-life] Personal communication, Jan. 18, 1994 and Jun. 28, 1995. [174] KUSEKA, I. and SILBERMAN, T. Male motivation impact evaluation survey. Harare, Zimbabwe, Zimbabwe National Family Planning Council, Jun. 1990. 152 p. [175] LABBOK, M.H. and LAUKARAN, V.H. Postpartum family planning choices for the lactating woman: The use of Norplant and Depo-Provera.[Abstract 3231] In: American Public Health Association (APHA). Abstracts: American Public Health Association 122nd Annual Meeting and Exhibition, Oct. 30-Nov. 3, 1994, Washington, D.C. Washington, D.C., APHA, 1994 p. 368. [176] LAING, J.E. Continuation and effectiveness of contraceptive practice: A cross-sectional approach. Studies in Family Planning 16(3): 138-153. May-Jun. 1985. [177] LAMA, U.C.S. (John Snow) [Logistics for injectables] Personal communication, Jan. 14, 1994. [178] LAMBE, M., HSIEH, C.-C., TRICHOPOULOS, D., EKBOM, A., PAVIA, M., and ADAMI, H.-O. Transient increase in the risk of breast cancer after giving birth. New England Journal of Medicine 331(1): 5-9. Jul. 7, 1994. [179] LANDE, R.E. and BLACKBURN, R. Pharmacists and family planning. Population Reports, Series J, No. 37. Baltimore, Johns Hopkins School of Public Health, Population Information Program, Nov. 1989. 32 p. [180] LEE, N.C., ROSERO-BIXBY, L., OBERLE, M.W., GRIMALDO, C., WHATLEY, A.S., and ROVIRA, E.Z. A case-control study of breast cancer and hormonal contraception in Costa Rica. Journal of the National Cancer Institute 79(6): 1247-1254. Dec. 1987. [181] LEN, F.R., HURTADO, R., and MONGE, R., Provider knowledge concerning Depo-Provera and other contraceptives before and after training: A study in rural Peru. Dec. 31, 1992. 27 p. (Unpublished) [182] LERMAN, C., MOLYNEAUX, J.W., MOELJODIHARDJO, S., PANDJAITAN, S. The correlation between family planning program inputs and contraceptive use in Indonesia. Studies in Family Planning 20(1): 26-37. Jan.-Feb. 1989. [183] LIAN, A.P., LEVENSON, A.G., LAYDE, P.M., SHELTON, J.D., HATCHER, R.A. POTTS, M., and MICHELSON, M.J. Risk of breast, uterine corpus, and ovarian cancer in women receiving medroxyprogesterone injections. Journal of the American Medical Association 249(21): 2909-2912. Jun. 2, 1983. [184] LIEW, D.F.M., NG, C.S.A., YONG, Y.M., and RATNAM, S.S. Long-term effects of Depo-Provera on carbohydrate and lipid metabolism. Contraception 31(1): 51-64. Jan. 1985. [185] LISKIN, L. and QUILLIN, W.F. Long-acting progestins-Promise and prospects. Population Reports, Series K, No. 2. Baltimore, Johns Hopkins School of Public Health, Population Information Program, May 1983. 40 p. [186] LITTLEFIELD, J. (Margaret Sanger Center International) [Noristerat in Namibia Personal communication, Mar. 4, 1993 and Feb. 15, 1995. [187] LUBIS, F. (Yayasan Kusuma Buana) [Injectables in Indonesia] Personal communication, Dec. 7, 1993. [188] LUBIS, F., FAJANS, P., and SIMMONS, R. Maintaining technical quality of care in the introduction of Cyclofem in a national family planning program: Findings from Indonesia. Contraception 49)5): 527-541. May 1994. [189] MAIN, A. and SATTERTHWAITE, W. Anaphylactic shock following an injection of depo-provera. [Letter to the editor] British Journal of Family Planning 13(4): 135. Jan. 1988. [190] MAINWARING, R., HALES, H.A., STEVENSON, K., HATASAKA, H.H., POULSON, A.M., JONES, K.P., and PETERSON, C.M. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives. Contraception 51(3): 149-153. Mar. 1995. [191] MALAWI. NATIONAL STATISTICAL OFFICE (NSO). and MACRO INTERNATIONAL (MI). DEMOGRAPHIC AND HEALTH SURVEYS. Malawi Demographic and Health Survey 1992. Zomba, Malawi, and Calverton, Maryland, NSO. and MI, Jan. 1994. 221 p. [192] MALONE, K.E., DALING, J.R., and WEISS, N.S. Oral contraceptives in relation to breast cancer. Epidemiologic Reviews 15(1):80-97. 1993. [193] MATI, J.K.G., AGGARWAL, V.P., and FRASER, R.B. A 3-year follow-up study of use of norethisterone oenanthate in Nairobi, Kenya. Journal of Obstetrics and Gynaecology of Eastern and Central Africa 1(2): 73-76. Jun. 1982. [194] MATTSON, R.H., CRAMER, J.A., CALDWELL, B.V., and SICONOLFI, B.C. Treatment of seizures with medroxyprogesterone acetate: Preliminary report. Neurology 34(9): 1255-1258. Sep. 1984. [195] MAULDIN, W.P. and MILLER, V.C. Contraceptive use and commodity costs in developing countries, 1994-2005. New York, United Nations Population Fund, 1994. (Technical Report No. 18) 67 p. [196] MAZIS, M., MORRIS, L.A., and GORDON, E. Patient attitudes about two forms of prined oral contraceptive information. Medical Care 16(12):1045-1054. Dec. 1978. [197] MCCANN, M.F., LISKIN, L.S., PIOTROW, P.T., RINEHART, W., and FOX, G. Breast-feeding, fertility, and family planning. Population Reports, Series J, No. 24. Baltimore, Johns Hopkins School of Public Health, Population Information Program, Mar. 1984 (Rev.) 52 p. [198] MCCARTHY, J. (Columbia University) [Injectables vs. other methods] Personal communication, Apr. 28, 1995. [199] MCDANIEL, E.B. (McCormick Christian Hospital) [McCormick Family Planning Program] Personal communication, May 1, 1995. [200] MCEWAN, J.A., GRIFFIN, M., FOTHERBY, K., and TRAYNER, I. Long-term use of depot-norethisterone enanthate: Effect on blood lipid frictions. Contraception 46(1): 49-60. Jul. 1992. [201] MCEWAN, J.A. and GRIFFIN, M. Long-term use of depot-norethisterone enanthate: Effect on blood coagulation factors and menstrual bleeding patterns. Contraception 44(6): 639-648. Dec. 1991. [202] MCFARLANE, C.P., FRIEDMAN, J.S., MORRIS, L., and GOLDBERG, H.I. Contraceptive Prevalence Survey, Jamaica 1993: 3 Sexual experience, contraceptive practice and fertility. [Kingston], Jamaica, National Family Planning Board, Oct. 1994. 131 p. [203] MCNEIL, B.J., PAUKER, S.G., SOX, H.C., Jr., and TVERSKY, A. On the elicitation of preferences for alternative therapies. New England Journal of Medicine 306(21): 1259-1262. May 27, 1982. [204] MCNEILL, E. (USAID) [AID distribution of DMPA] Personal communication, Dec. 22, 1994. [205] MEADE, C.W., CASARIN, L.P.M., DIAZ, M.A., AQUADO, A.G., ZACARIAS, L.S., HOLCK, S., DIETHELM, P. and ANNUS, J. A clinical study of norethisterone enanthate in rural Mexico. Studies in Family Planning 15(3): 143-148. May-Jun. 1984. [206] MEHAFFEY, A. (Family Planning Association/New Zealand) [Injectable contracepties] Personal communication, Apr. 6, 1995. [207] MELTON, L.J., 3rd, KAN, S.H., WAHNER, H.W., and RIGGS, B.L. Lifetime fracture risk: An approach to hip fracture risk assessment based on bone mineral density and age. Journal of Clinical Epidemiology 41(10): 985-994. 1988. [208] MENG, Y.-X., JIANG, H.-Y., CHEN, A.-J., LU, F.-Y., YANG, H., ZHANG, M.-Y., SHEN, K.-Y, SUN, D.-L., SHAO, Q.-X., and FOTHERBY, K. Hemostatic changes in women using a monthly injectable contraceptive for one year. Contraception 42(4): 455-466. Oct. 1990. [209] MENG, Y.-X. and VIRUTAMASEN, P. Effect of norethisterone enanthate on endometrial bleeding and changes in coagulation function, ovarian hormones and endometrial histology in Thai women. Contraception 44(1): 73-82. Jul. 1991. [210] MIGALLOS, G.T. (Kabilikat) [Social marketing of injectables] Personal communication, Nov. 11, 1994. [211] MIRZA, T. (ICDDR/Bangladesh) [Injectibles] Personal communication, Dec. 28, 1994. *[212] MIRZA, T., BARKAT-E-KHUDA, ASHRAF, A., HUMAYUN, K., HAQUE, I., ALAM, S., MOZUMDER, K., and RAHMAN, M. Doorstep delivery of injectable contraceptives in eight thanas: Key findings. In: Barkat-e-Khuda, Mirza, T., and Ahmed, S., eds. Lessons learned on doorstep delivery of injectable contraceptives: Workshop proceedings. Dhaka, International Centre for Diarrhoeal Disease Research, 1994. p. 25-41. [213] MOSTERT, W.P. Recent trends in fertility in South Africa. In: Mostert, W.P. and Lotter, J.M., eds. South Africa's demographic future. Pretoria, South Africa, Human Sciences Research Council, 1990. p. 63-73. [214] NACHTIGALL, M.J., SCHWARTZ, L.B., and OLIVE, D.L. Endometriosis. In: Scott, J.R., Disaia, P.J., Hammond, C.b., and Spellacy, W.N., eds. Danforth's Obstetrics and gynecology. 7th ed. Philadelphia, J.B. Lippincott, 1994. p. 757-769. [215] NAESSEN, T., OLSSON, S.-E., and GUDMUNDSON, J. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Contraception 52:35-39. 1995. [216] NAIROBI CITY COMMISION (NCC). and POPULATION COUNCIL (PC). and PATHFINDER FUND (PF). A situation analysis of the Nairobi City Commission family planning clinics. Nairobi, NCC. PC. PF, Dec. 1991. 44 p. (Mimeo) [217] NARKAVONNAKIT, T., BENNETT, T., and BALAKRISHNAN, T.R. Continuation of injectable contraceptives in Thailand. Studies in Family Planning 13(4): 99-105. Apr. 1982. [218] NATIONAL INSTITUTE FOR POPULATION RESEARCH AND TRAINING (NIPORT). Bangladesh Demographic and Health Survey 1993-94: Preliminary report. Dhaka, Bangladesh. and Calverton, Maryland, NIPORT. and Mitra and Associates. and Macro International Inc., Jul. 1994. 37 p. [219] NDIAYE, S., DIOUF, P.D., and AYAD, M. Enquete Demographique et de Sante au Senegal (EDS-II) 1992/93. [Demographic and Health Survey of Senegal (EDS-II) 1992/93.][FRE] Dakar, Senegal. and Calverton, Maryland, Senegal Ministry of Finance, Treasury and Planning. Division of Demographics and Statistics. and Macro International, Apr. 1994. 284 p. [220] NEW ERA, IIDS, and VARG (NIV) JOINT VENTURE. Nepal fertility, family planning and health survey (NFHS, 1991): Main report. [Draft] 1992. 192 p. [221] NEW ZEALAND CONTRACEPTION AND HEALTH STUDY GROUP. History of long-term use of depot-medroxyprogesterone acetate in patients with cervical dysplasia; case-control analysis nested in a cohort study. Contraception 50(5): 443-449. Nov. 1994. [222] NEW ZEALAND CONTRACEPTION AND HEALTH STUDY GROUP. Risk of cervical dysplasia in users of oral contraceptives, intrauterine devices or depot-medroxyprogesterone acetate. Contraception 50(5): 431-441. Nov. 1994. *[223] NEWTON, J.R., DARCANGUES, C., and HALL, P.E. Once-a-month combined injectable contraceptives. Journal of Obstetrics and Gynaecology 14(Suppl. 1): S1-S34. Mar. 1994. [224] NGALLABA, S., KAPIGA, S.H., RUYOBA, I., and BOERMA, J.T. Tanzania Demographic and Health Survey 1991-92. Dar es Salaam, Tanzania. and Columbia, Maryland, Tanzania Bureau of Statistics. and Marco International Inc., Jun. 1993. 324 p. [225] NIGERIA. FEDERAL MINISTRY OF HEALTH (NMOH). PRIMARY HEALTH CARE UNIT. FAMILY HEALTH SERVICES PROJECT. and OBAFEMI AWOLOWO UNIVERSITY (OAU). OPERATIONS RESEARCH UNIT AND NETWORK. and POPULATION COUNCIL (PC). AFRICA OR/TA PROJECT. Nigeria: The family planning situation analysis study. [Lagos], Nigeria, NMOH. and lle-lfe, Nigeria, OAU. and [Nairobi], PC, [1992]. 48 p. *[226] O'BRIEN, B. `What are my chances doctor?' A review of clinical risks. London, Office of Health Economics, Nov. 1986. (Studies of Current Health Problems No. 84) 44 p. [227] OBERLE, M.W., ROSERO-BIXBY, L., IRWIN, K.L., FORTNEY, J.A., LEE, N.C., WHATLEY, A.S., and BONHOMME, M.G. Cervical cancer risk and use of depot-medroxyprogesterone acetate in Costa Rica. International Journal of Epidemiology 17(4): 718-723. Dec. 1988. [228] ODDENS, B.J., VEMER, H.M., VISSER, A.P., and KETTING, E. Contraception in Germany: A review. Advances in Contraception 9(2): 105-116. Jun. 1993. [229] OWENS, R. (John Snow) [Logistics for injectables] Personal communication, Jan. 14, 1994. [230] OYELOLA, O.O. Fasting plasma lipids, lipoproteins and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives. Contraception 47(5): 445-454. May 1993. [231] PALMER, S.M., SHERRILL J., and MORRISON, J.C. Diseases of the blood. In: Danforth, D.N. and Scott, J.R., eds. Obstetrics and gynecology. 5th ed. Philadelphia, J.B. Lippincott, 1986. p. 531-538. [232] PARDTHAISONG, T. and GRAY, R. In utero exposure to steroid contraceptives and outcome of pregnancy. American Journal of Epidemiology 134(8): 795-803. Oct. 15, 1991. [233] PARDTHAISONG, T. and GRAY, R.H. The return of fertility following discontinuation of oral contraceptives in Thailand. Fertility and Sterility 35(5): 532-534. May 1981. [234] PARDTHAISONG, T., GRAY, R.H., MCDANIEL, E.B., and CHANDACHAM, A. Steroid contraceptive use and pregnancy outcome. Teratology 38(1): 51-58. Jul. 1988. [235] PARDTHAISONG, T., GRAY, R.H., and MCDANIEL, E.B. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in northern Thailand. Lancet 1(8166): 509-511. Mar. 8, 1990. [236] PARDTHAISONG, T. Return of fertility after use of the injectable contraceptive Depo-Provera: Up-dated data analysis. Journal of Biosocial Science 16(1): 23-34. 1984. [237] PARTHAISONG, T., YENCHIT, C., and GRAY, R. The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation. Contraception 45(4): 313-324. Apr. 1992. [238] PARIANI, S., HEER, D.M., and VAN ARSDOL, M.D., Jr. Does choice make a difference to contraceptive use? Evidence from East Java. Studies in Family Planning 22(6): 384-390. Nov.-Dec. 1991. [239} PARKIN, D.M., PISANI, P., and FERLAY, J. Estimates of the worldwide incidence of eighteen major cancers in 1985. International Journal of Cancer 54(4): 594-606. Jun. 19, 1993. [240] PARVEEN, L., CHOWDHURY, A.Q., and CHOWDHURY, Z. Injectible contraception (medroxyprogesterone acetate) in rural Bangladesh. Lancet 2(8045): 946-948. Nov. 5, 1977. [241] PATTAWICHAIPORN, S. (Planned Parenthood Association of Thailand) [Injectables in Thailand] Personal communication, Jun. 28, 1993. [242] PAUL, C., SKEGG, D.C.G., SMEIJERS, J., and SPEARS, G.F.S. Contraceptive practice in New Zealand. New Zealand Medical Journal 101(859): 809-813. Dec. 14, 1988. [243] PAUL, C., SKEGG, D.C.G., and SPEARS, G.F.S., Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer. British Medical Journal 299(6702): 759-762. Sep. 23, 1989. [244] PEARSON, C. (National Womens Health Network) [Talks with the FDA on DMPA] Personal communication, Feb. 13, 1995. [245] PEREZ PALACIOS, G. (Mexico. Ministry of Health) [Injectibles in the Mexican family planning program] Personal communication, Jan. 27, 1994. [246] PERRY, S. (John Snow) [Logistics for injectables] Personal communication, Jan. 23, 1994. [247] PETERSON, L.S. Contraceptive use in the United States: 1982-90. Advance Data 260: 1-15. Feb. 14, 1995. [248] PHILIPPINES. DEPT OF HEALTH (DOH). DMPA: The injectable contraceptive. An information kit. [Loose-leaf booklet] [Manila], DOH, 1994. 10 p. [249] PHILIPPINES. NATIONAL STATISTICS OFFICE (NSO). and MACRO INTERNATIONAL (MI). DEMOGRAPHIC AND HEALTH SURVEYS. National Demographic Survey 1993. Manila. and Calverton, Maryland, NSO. and MI, May 1994. 228 p. [250] PHILIPS, M. The patient's right not to know. Johns Hopkins Magazine 46(5):3. [251] PHILIPPS, J.F. A case study of contraceptive introduction: Domiciliary DMPA services in rural Bangladesh. Presented at the Committee on Population National Academy of Sciences seminar on the Demographic and Programmatic Consequences of Contraceptive Innovations, Washington, D.C., Oct. 6-7, 1988. 32 p. [252] PLATA, S. and BACHMAN, G. (SOMARC) [Social marketing of injectables] Personal communication, Dec. 21, 1993. [253] POPULATION COUNCIL. First-year comparison of IUD and implant codition rates: Conditions for which percentages with condition were significantly higher for implant subjects. Table 21. Presented at public hearings on Norplant subdermal implants before the Fertility and Maternal Health Drugs Advisory Committee of the US Food and Drug Administration, Rockville, Maryland, Apr. 1989. [254] POPULATION COUNCIL. Operations research proposal: Lima office. 1993. 20 p. (Unpublished) [255] POPULATION COUNCIL (PC). INOPAL II. and FAMILY HEALTH INTERNATIONAL (FHI). DMPA findings, Peru and Ecuador. Presented at the Co-operating Agencies Meeting of the US Agency for International Development, Washington, D.C., Feb. 24, 1994. 2 p. [256] PRABHAVATHI, K. and SHESHADRI, A. Pattern of IUD use: A follow-up of acceptors in Mysore. Journal of Family Welfare 35(1): 3-16. Sept. 1988. [257] PROGRAM FOR APPROPRIATE TECHNOLOGY IN THEALTH (PATH). information for public health programs: Uniject prefilled syringe. Seattle, Washington, PATH, [1995]. 8 p. (Mimeo) [258] PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH). SoloShot. Seattle, Washington, PATH, May 1993. 1 p. (Mimeo) (*) [259] PROGRAM FOR INTERNATIONAL TRAINING IN HEALTH (INTRAH). Guidelines for clinical procedures in family planning: A reference for trainers. 2nd ed. Chapel Hill, North Carolina, INTRAH, 1992. 352 p. [260] PROPER, W (John Snow) [Logistics for contraceptives] Personal communication, Feb. 13, 1995. [261] QUINTONG, J.B. Follow-up study of DMPA acceptors 6-8 years (72 to 96 mos.) post-acceptancecavite, Aug. 1987. [Manila], Philippines. Aug. 1987. 5 p. (Unpublished) [262] QUINTONG, J.B. (Philippines, Department of Health) [DMPA follow-up study results] Personal communication, Jul. 6, 1993. [263] RAFIQUZ-ZAMAN, A.K.M. (Bangladesh Ministry of Health and Family Welfare) [Injectables through Bangladesh government] Personal communication, Mar. 24, 1994. [264] RAHMAN, S.S., JABEEN, S., MALAKAR, M., RAHMAN, S., KHATOON, J., AHMED, N., CHOWDHURY, S.M., HOLCK, S.E., BUSCA, B., and AKHTER, H. introduction of the injectable contraceptive NET-EN into family planning clinics in Banglaesh. Bulletin of the World Health Organization 63(4): 785-791. 1985. [265] RAMAN-WILMS, L., TSENG, A.L.-I., WIGHARDT, S., EINARSON, T.R., and KOREN, G. Fetal genital effects of first-trimester sex hormone exposure: A meta-analysis. Obstetrics and Gynecology 85(1): 141-149. Jan. 1995. [266] REFENO, G., RABEZA, V., MBOUP, G., and SCHOEMAKER, J. Enquete Nationale Demographique et Sanitaire 1992. [National Demographic and Health Survey 1992.] Antananarivo, Madagascar. and Calverton, Maryland, Madagascar National Center for Research on the Environment. and Macro International. Feb. 1994. 248 p. (*) [267] RILEY, A.P., STEWART, M.K., and CHAKRABORTY, J. Program- and method-related determinants of first DMPA use duration in rural Bangladesh. Studies in Family Planning 25(5): 255-267. Sept.-Oct. 1994. [268] ROBEY, B., RUTSEIN, S.O., MORRIS, L., and BLACKBURN, R. The reproductive revolution: New survey findings. Population Reports, Series M, No. 11. Baltimore, Johns Hopkins School of Public Health, Population Information Program, Dec. 1992. 44 p. [269] ROSENBLATT, K.A., and THOMAS, D.B. Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer. International Journal of Cancer 49: 182-185. 1991. [270] SALEM, H.T., SALAH, M., ALY, M.Y., THABET, A.I., SHAABAN, M.M., and FATHALLA, M.F. Acceptability of injectable contraceptives in Assiut, Egypt. Contraception 38(6): 697-710. Dec. 1988. [271] SANG, G.W., SHAO, Q.X., GE, R.S., et al. A multicentered phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given monthly by intramuscular injection to Chinese women: 1. Contraceptive efficacy and side effects. Contraception 51(3): 167-183. Mar. 1995. [272] SANG, G.W., SHAO, Q.X., GE, R.S., et al. A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given monthly by intramuscular injection to Chinese women: 2. The comparison of bleeding patterns. Contraception 51(3): 185-192. Mar. 1995. [273] SCHAEFER, L. (JHPIEGO) [Infection prevention for injectables] Personal communication, Jun. 20 and 22, 1995. [274] SCHROCK, R (Upjohn) [Allergic reactions to DMPA] Personal communication, Dec. 12, 1994. [275] SCHROEDER, B. (Jacksonville, Florida Hospital) [Transcript of interview with DMPA user] Personal communication, Aug. 12, 1993. [276] SCHWALLIE, P.C. and ASSENZO, J.R. Contraceptive use-efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertility and Sterility 24(5): 331-339. May 1973. [277] SCHWALLIE, P.C. and ASSENZO, J.R. The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: A review. Contraception 10(2): 181-202. Aug. 1974. [278] SEVERY, L.J., THAPA, S., ASKEW, I., and GLOR, J. Menstrual experiences and beliefs. A multicountry study of relationships with fertility and fertility regulating methods. Women and Health 20(2): 1-20. 1993. [279] SHAABAN, M.M. Contraception with progestogens and progesterone during lactation. Journal of Steroid Biochemistry and Molecular Biology 40(4-6): 705-710. 1991: [280] SHAARAWY, M. and EL-SHENOUFY, O. Serum glycocholic and glycochenodeoxycholic acids in injectable contraceptives--Noristerat and depot provera users. Arab Journal of Laboratory Medicine 18(1): 171-177. Jan 1992. [281] SIMMONS, R., FAJANS, P., and LUBIS, F. Contraceptive introduction and the management of choice: The role of Cyclofem in Indonesia. Contraception 49(5): 509-525. May 1994. [282] SIMPSON, J.L. and PHILLIPS, O.P. Spermicides, hormonal contraception and congenital malformations. Advances in Contraception 6(3): 141-167. 1990. [283] SKEGG, D.C.G. Monthly combined injectable contraceptives and neoplasia. Contraception 49(5): 435-439. May 1994. (*) [284] SKEGG, D.C.G., NOONAN, E.A., PAUL, C., SPEARS, G.F.S., MEIRIK, O., and THOMAS, D.B. Depot medroxyprogesterone acetate and breast cancer: A pooled analysis of the World Health Organization and New Zealand studies. Journal of the American Medical Association 273(10): 799-804. Mar. 8, 1995. [285] SOLHEIM, F. The assessment of quality of life in women treated with Depo-Provera in Sweden. In: Zambrano, D., ed. Depo-Provera (medroprogesterone acetate) for contraception: A current perspective of scientific, clinical and social issues. Procedings of an international symposium held on 19-20 Nov. 1992, 2nd ed. Oxford, Oxford Clinical Communications, 1992. p. 61-72. [286] SOMBOONSUK, A., XUTO, N., GRAY, R.H., and GROSSMAN, R.A. A field study of the choice and continuity of use of three contraceptive methods in a rural area of Thailand. Journal of Biosocial Science 10(2): 209-216. Apr. 1978. [287] SOWERS, M.R. and GALUSKA, D.A. Epidemiology of bone mass in premenopausal women. Epidemiologic Reviews 15(2): 374-398. 1993. [288] SPICEHANDLER, J. and SIMMONS, R. Contraceptive introduction reconsidered: A review and conceptual framework. Geneva, World Health Organization, 1994. 34 p. [289] SPINELLI, A., GRANDOLFO, M., DONATI, S., and MEDDA, E. Family planning in Italy. Advances in Contraception 9(2): 153-160. Jun. 1993. [290] STANFORD, J.L. Oral contraceptives and neoplasia of the ovary. Contraception 43(6): 543-556. Jun. 1991. [291] STANFORD, J.L., and THOMAS, D.B. Depot-medroxyprogresterone acetate (DMPA) and risk of epithelial ovarian cancer. International Journal of Cancer 49: 191-195. 1991. [292]. STEELE VERME, C. and BENOIT, E. Family planning counseling: The international experience. Meeting report, Istanbul, Turkey, Apr. 1992. New York, Association for Voluntary Surgical Contraception, 1993. 62 p. [293] STEINGLASS, R. (BASICS) [Infection prevention] Personal communication, Jul 21, 1995. [294] STEINGLASS, R., BOYD, D., GRABOWSKY, M., LAGHARI, A.G., KHAN, A., QAVI, A., and EVANS, P. Safety, effectiveness and ease of use of a non-reusable syringe in a developing country immunization programme. Bulletin of the World Health Organization 73(1): 57-63. 1995. [295] SUYONO, H., SAFFITZ, and RIMON, J.G., 2nd. Indonesia: The Blue Circle Campaign. (Working Paper) Baltimore, Johns Hopkins University, Population Communication Services, Oct. 1989. 12 p. [296] SZAREWSKI, A., HOLLINGWORTH, B., and GUILLEBAUD, J. Depot medroxyprogesterone acetate and osteoporosis: Monitor serum oestradiol concentration in users. British Medical Journal 308(6930): 717. Mar. 12, 1994. [297] TANZANIA. MINISTRY OF HEALTH (TMOH). and POPULATION COUNCIL (PC). AFRICA OR/TA PROJECT. Tanzania: The family planning situation analysis study. Dar es Salam, Tanzania, TMOH. and Nairobi, PC, 1992. 45 p. [298] TAYLOR, W.E. (Planned Parenthood Association of Sierra Leone) [DMPA in Sierra Personal communication, Jun. 21, 1993. (*) [299] TECHNICAL GUIDANCE WORKING GROUP. Recommendations for updating selected practices in contraceptive use: Results of a technical meeting. (Vol. 1) Chapel Hill, North Carolina, Program for International Training in Health, Nov. 1994. 130 p. (Mimeo) [300] THOMAS, D.B., MOLINA, R., CUEVAS, H.R., et al. Monthly injectable steroid contraceptives and cervical carcinoma. American Journal of Epidemiology 130(2): 237-247. 1989. (*) [301] THOMAS, D.B. and NOONAN, E.A. Breast cancer and depot-medroxyprogesterone acetate: A multinational study. Lancet 338(8771): 833-838. Oct. 5, 1991. [302] THOMAS, D.B. and RAY, R.M. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. International Journal of Cancer 49: 186-190. 1991. [303] THOMAS, D.B. and RAY, R.M. Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer. Contraception 45: 299-312. 1992. [304] THOMAS, D.B., YE, Z, RAY, R.M., and THE WHOE COLLABORATIVE STUDY OF NEOPLASIA AND STEROID CONTRACEPTIVES. Cervical carcinoma in situ and use of depot-medroxyprogesterone acetate (DMPA). Contraception 51(1): 25-31. Jan. 1995. (*) [305] TIETJEN, L., CRONIN, W., and MCINTOSH, N. Infection prevention for family planning service programs: A problem-solving reference manual. Durant, Oklahoma, Essential Medical Information System, 1992, 254 p. [306] TIMYAN, J. (Population Services International) [Social marketing of injectables] Personal communication, Dec. 8, 1993. [307] TIPPING, S.L. Trip report: Nepal. Dec. 6-18, 1993. Washington, D.C., SOMARC/Futures Group, 1993. [308] TRELOAR, A.E., BOYNTON, R.E., BEHN, B.G., and BROWN, B.W. Variation of the human menstrual cycle through reproductive life. International Journal of Fertility 12(1, Pt.2): 77-126. Jan.-Mar. 1967. [309] TSAKOK, F.H.M., KOH, S., YUEN, R., and RATNAM, S.S. Coagulation studies in Asian women using injectable progestogen for contraception. International Journal of Gynaecology and Obstetrics 18(2): 105-108. Sep.-Oct. 1980. [310] TURKEY. MINISTRY OF HEALTH (MOH), and HACETTEPE UNIVERSITY (HU). INSTITUTE OF POPULATION STUDIES. and DEMOGRAPHIC AND HEALTH SURVEYS (DHS). MACRO INTERNATIONAL. Turkey Demographic and Health Survey 1993. Ankara, Turkey. and Calverton, Maryland, MOH. and HU. and DHS, Oct. 1994. 247 p. [311] UNITED STATES, AGENCY FOR INTERNATIONAL DEVELOPMENT (AID). DMPA: Next steps. [Washington, D.C., USAID, 1994]. 12 p. (Mimeo) [312] UPJOHN COMPANY (UC). Contraceptive confidence 3 months at a time. Kalamazoo, Michigan, UC, 1994. 20 p. [313] UPJOHN COMPANY (UC). Depo-Provera for contraception: Information for Public Board of Inquiry on Depo-Provera: Responses to the Boards questions. Kalamazoo, Michigan, UJ, Jun. 25, 1982. 155 p. [314] VESSEY, M.P. Benefits and risks of combined oral contraceptives. Methods of information in Medicine 32(3): 222-224. Apr. 1993. [315] VIRUTAMASEN, P. Long-acting injectable contraceptives--Current status. In: Palan, V.T. and Nawi, M., eds. Recent advances in contraceptives tecnology: Proceedings of the seminar held on 14-20 Oct. 1987 in Chiang Mai, Thailand. London, International Planned Parenthood Federation, 1987. p. 86-92. [316] VIRUTAMASEN, P., WANGSUPHACHART, S., REINPRAYOON, D., KRIENGSINYOT, R., LEEPIPATPAIBOON, S., and GUA, C. Trabecular bone in long-term depot-medroxyprogesterone acetate users. Asia-Oceania Journal of Obstetrics and Gynaecology 20(3): 269-274. Sep. 1994. [317] VOIGT, L.F. and WEISS, N.S. Epidemiology of endometrial cancer. Cancer Treatment Research 49: 1-21. 1989. [318] WARNER-ROWE, R. (PATH) [Cyclofem] Personal communication, Oct. 14, 1993, Apr. 20, 1995, and Aug. 9, 1995. [319] WEBB, S. and HOLMAN, D. A survey of contraceptive use and unplanned pregnancy in Perth, Western Australia. Australian Journal of Public Health 16(4): 382-386. Dec. 1992. [320] WEINER, E. and JOHANSSON, E.D.B. The influence of norethisterone oenanthate on ovarian function. Acta Endocrinologica 83(2): 386-392. Oct. 1976. [321] WEISBERG, E. the Depo-Provera controversy: Regulatory, medical and social issues. In: Zambrano, D., ed. Depo-Provera (medroxyprogesterone acetate) for contraception: A current perspective of scientific, clinical and social issues. Proceedings of an international symposium held on 19-20 Nov. 1992. 2nd ed. Oxford, Oxford Clinical Communications, 1993. p. 27-38. [322] WEISZ, J., ROSS, G.T., and STOLLEY, P.D. Report of the Public Board of Inquiry on Depo-Provera. Oct. 26, 1984. 207 p. (Unpublished) [323] WERAWATGOOMPA, P., and DUSITSIN, N. The effect of injectable norethisterone oenanthate on ovarian hormones in Thai women. Contraception 21(3): 299-309. Mar. 1980. [324] WHELAN, E.M. Attitudes toward menstruation. Studies in Family Planning 6(4): 106-108. Apr. 1975. [325] WILLIAMS, E.M.I., JONES, L., VESSELY, M.P., and MCPHERSON, K. Short term increase in risk of breast cancer associated with full term pregnancy. British Medical Journal 300(6724): 578-579. Mar. 3, 1990. [326] WILSON, J.G. and BRENT, R.L. Are female sex hormones teratogenic? American Journal of Obstetrics and Gynecology 141(5): 567-580. Nov. 1, 1981. (*) [327] WORLD HEALTH ORGANIZATION. A cross-cultural study of menstruation: Implications for contraceptive development and use. Studies in Family Planning 12(1): 3-16. Jan. 1981. [328] WORLD HEALTH ORGANIZATION (WHO). The effect of female sex hormones on fetal development and infant health. Geneva, WHO, 1981, (WHO Technical Report Series No. 657) 76 p. [329] WORLD HEALTH ORGANIZATION. Effects of hormonal contraceptives on breast milk composition and infant growth. Studies in Family Planning 19(6): 361-369. Nov.-Dec. 1988. [330] WORLD HEALTH ORGANIZATION. Facts about injectable contraceptives: Memorandum from a WHO meeting. Bulletin of the World Health Organization 60(2): 199-210. 1982. (*) [331] WORLD HEALTH ORGANIZATION. Facts about once-a-month injectable contraceptives: Memorandum from a WHO meeting. Bulletin of the World Health Organization 71(6): 677-689. 1993. [332] WORLD HEALTH ORGANIZATION. Improving access to quality care in family planning Medical criteria in selected methods of contraception. (Draft) [1994, 1995]. 31 p. (*) [333] WORLD HEALTH ORGANIZATION (WHO). Injectable contraceptives: Their role in family planning care. Geneva, WHO, 1990. 117 p. [334] WORLD HEALTH ORGANIZATION. A multicentre comparative study of serum lipids and apolipoproteins in long-term users of DMPA and a control group of IUD users. Contraception 47(2): 177-191. Feb. 1993. [335] WORLD HEALTH ORGANIZATION. A multi-centered pharmacokinetic, pharmacodynamic study of once-a-month injectable contraceptives: 1. Different doses of HRP112 and of depoprovera. Contraception 36(4): 441-457. Oct. 1987. [336] WORLD HEALTH ORGANIZATION. A multicentered Phase III comparatives study of two hormonal contraceptive preprations given once-a-month by intramuscular injection: 1. Contraceptive efficacy and side effects. Contraception 37(1): 1-20. Jan. 1988. [337] WORLD HEALTH ORGANIZATION. A multicentered Phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection. 2. The comparison of bleeding patterns. Contraception 40(5): 531-551. Nov. 1989. [338] WORLD HEALTH ORGANIZATION. A multicentered Phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100mg or 150mg: 1. Contraceptive efficacy and side effects. Contraception 34(3): 223-235. Sep. 1986. [339] WORLD HEALTH ORGANIZATION. A multicentered Phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100mg or 150mg: 2. The comparison of bleeding patterns. Contraception 35(6): 591-610. Jun. 1987. [340] WORLD OF HEALTH ORGANIZATION. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: Norethisterone oenanthate and medroxyprogesterone acetate: 1. Use-effectiveness. Contraception 15(5): 513-533. May 1977. [341] WORLD HEALTH ORGANIZATION. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: Norethisterone oenanthate and medroxyprogesterone acetate: 2. Bleeding patterns and side effects. Contraception 17(5): 395-406. May 1978. [342] WORLD HEALTH ORGANIZATION. Multinational comparative clinical trial of long-acting injectable contraceptives: Norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate: Final report. Contraception 28(1): 1-20. Jul. 1983. [343] WORLD HEALTH ORGANIZATION (WHO). The prevalence of anaemia in woman: A tabulation of available information. (2nd ed.) Geneva, WHO, 1992. 100 p (Mimeo) [344] WORLD HEALTH ORGANIZATION (WHO). Reducing the risk of unsafe injections in immunization programmes: The role of injection equipment. Geneva, WHO, 1994. (Logistics for Health Information Series 94.2 13 p. [345] WORLD HEALTH ORGANIZATION (WHO). Yamoussoukro declaration on the safety of injections. Geneva, WHO, [1994]. 2 p. [346] WORLD HEALTH ORGANIZATION. SPECIAL PROGRAMME OF RESEARCH, DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION. Safety of the long-acting injectable contraceptive Depo-Provera. Oct. 30, 1978 7 p. (Unpublished) [347] WORLD HEALTH ORGANIZATION. TASK FORCE FOR EPIDEMIOLOGICAL RESEARCH ON REPRODUCTIVE HEALTH. Progestogen-only contraceptives during lactation: 1. Infant growth. Contraception 50(1): 35-53. Jul. 1994. [348] WORLD HEALTH ORGANIZATION. TASK FORCE FOR EPIDEMIOLOGICAL RESEARCH ON REPRODUCTIVE HEALTH. Progestogen-only contraceptives during lactation: 2. Infant development . Contraception 50(1): 55-68. Jul. 1994. [349] WORLD HEALTH ORGANIZATION. TASK FORCE ON ORAL CONTRACEPTIVES. A randomized double-blind study of six combined oral contraceptives. Contraception 25(3): 231-241. Mar. 1982. [350] WYATT, H.V. The popularity of injections in the Third World: Origins and consequences for poliomyelitis. Social Science and Medicine 19(9): 911-915. 1984. [351] WYNN, R.M. Obstetrics and gynecology: The clinical core, 5th ed. Philadelphia, Lea & Febiger, 1992. 373 p. [352] YASER, Y. (Turkish Family Health and Planning Foundation) [Social Marketing of Depo-Proveral Personal communications, Jan. 31 and Nov. 14, 1994. [353] ZACEST, R., CUSHWAY, A., HAINES, and COS, J.W. Hypersensitivity reaction to Depo-Provera. Medical Journal of Australia 1(1): 12. Jan. 9, 1982. [354] ZACHARIAS, S., AGUILERA, E., JIMENEZ, J., ASSENZO, J.R., and ZAARTU, J.A. The effects of hormonal and non-hormonal contraceptives on human loctation and on the re- establishment of fertility. International Journal of Gynacology and Obstetrics 25(Suppl.): 249-255. 1987. [355] ZAMBRANO, D., ed. Depo-provera (medroxyprogesterone acetate) for contraception: A current perspective of scientific, clinical and social issues. Proceedings of an international symposium held on 19-20 Nov. 1992. Oxford, England, Oxford Clinical Communications, 1993. 74 p. [356] ZANARTU, J., AGUILERA, E., ZACHARIAS, S., JIMENEZ, J., and ASSENZO, J.R. Effects of hormonal and nonhormonal contraceptives on human lactation and re-establishment of fertility. Presented at World Health Organization/National Academy of Sciences Workshop on Breastfeeding and Fertility Regulation, Geneva, Feb. 17-24, 1982. 21 p. [357] ZANARTU, J. and NAVARRO, C. Fertility inhibition by an injectable propestogen acting for 3 months: a clinical survey of 130 fertile women treated with nonethisterone enanthate. Obstetrics and Gynecology 31(5): 627-633. May 1968. [358] ZIMBABWE, CENTRAL STATISTICAL OFFICE (CSO). and DEMOGRAPHIC AND HEALTH SURVEYS (DHS). MACRO INTERNATIONAL. Zimbabwe Demographic and Health Survey 1994: Preliminary report. Harare, Zimbabwe. and Calverton, Maryland, CSO, and DHS, Ja. 1995. 32 p. [359] ZIMMERMAN, A.W., HOLDEN, K.R., REITER, E.O., and DEKABAN, A.S. Medroxyprogesterone acetate in the treatment of seizures associated with menstruation. Journal of Pediatrics 83(6): 959-963. Dec. 1973.

ADDENDA

[360] BIERMAN, E.L. Atherosclerosis and other forms of arteriosclerosis. In: Isselbacher, K.J., Braunwald, E., Wilson, J.D., Martin, J.B. Fauci, A.S., and Kasper, D.L., eds. Harrison's principles of internal medicine. 13th ed. New York, McGraw-Hill, 1994. p. 1106-1116. [361] BROOKE, S. (PATH) [UniJect] Personal communication, August 9, 1995. [362] GALLAGHER, J.C., KABLE, W.T., and GOLDGAR, D. Effect of progestin therapy on cortical and trabecular bone: Comparison with estrogen. American Journal of Medicine 90(2): 171-178. February 1991. [363] HABERLAND, M. (Planned Parethood Federation of America) [Use of Depo-Provera by PPFA clients] Personal communication, June 6, 1995. [364] HATCHER, R.A., RINEHART, W., BLACKBURN, R., and GELLER, J. The essentials of contraceptive technology. Baltimore, Johns Hopkins Center for Communication Programs (forthcoming). [365] HUEZO, C. (IPPF) [Injection schedule for NET EN] Personal communication, August 10, 1995. [366] MATLOMELO, S., MALIEHE, T., SAKOANE, 'M., and LEWIS, G. A study of contraceptive drop-outs in Lesotho: Using focus groups to determine causes of discontinuation. 1989. 43 p. (Unpublished) [367] MATTSON, R.H. and REBAR, R.W. Contraceptive methods for women with neurologic disorders. American Journal of Obstetrics and Gynecology 168(6, Pt. 2): 2027-2032. June 1993. [368] MOGBISSI, K.S., and EVANS, T.N. Infertility. In: Danforth, D.N. and Scott, J.R., eds. Obstetrics and gynecology. 5th ed. Philadelphia, J.B. Lippincott, 1986. p. 927-947. [369] SHARMA, J.B. Smoking may explain findings. [Letter] British Medical Journal 308(6930): 717. March 12, 1994. [370] TRUSSELL, J., HATCHER, R.A., CATES, W. Jr., STEWART, F.H., and KOST, K. Contraceptive failure in the United states: An update. Studies in Family Planning 21(1): 51-54. January-February 1990. (*) [371] WORLD HEALTH ORGANIZATION (WHO). and UNITED NATIONS CHILDREN'S FUND. Injections: Pledge for safety. [Binder with text, VCR tape, and slides] Geneva, WHO, 1994.

COPYRIGHT 1995 Department of Health
COPYRIGHT 2004 Gale Group